The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”
Open accessAbstract
The ideal biomarker for Alzheimer’s disease (AD) should detect a fundamental feature of neuropathology and be validated in neuropathologically-confirmed cases; it should have a sensitivity >80% for detecting AD and a specificity of >80% for distinguishing other dementias; it should be reliable, reproducible, non-invasive, simple to perform, and inexpensive. Recommended steps to establish a biomarker include confirmation by at least two independent studies conducted by qualified investigators with the results published in peer-reviewed journals. Our review of current candidate markers indicates that for suspected early-onset familial AD, it is appropriate to search for mutations in the presenilin 1, presenilin 2, and amyloid precursor protein genes. Individuals with these mutations typically have increased levels of the amyloid Aβ 42 peptide in plasma and decreased levels of APPs in cerebrospinal fluid. In late-onset and sporadic AD, these measures are not useful, but detecting an apolipoprotein E e4 allele can add confidence to the clinical diagnosis. Among the other proposed molecular and biochemical markers for sporadic AD, cerebrospinal fluid assays showing low levels of Aβ 42 and high levels of tau come closest to fulfilling criteria for a useful biomarker.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Davis, R. E., Miller, S., Herrnstadt, C., Ghosh, S. S., Fahy, E., Shinobu, L. A., Galasko, D., Thal, L. J., Beal, M. F., Howell, N., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4526 · Cited by 341
RetractedAssociation of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease
Motter, R., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380413 · Cited by 701
Cytochrome oxidase deficiency in Alzheimer’s disease
Parker, W. D., Filley, C. M., & Parks, J. K. (1990) · Neurology · doi:10.1212/wnl.40.8.1302 · Cited by 598
Utility of the Apolipoprotein E Genotype in the Diagnosis of Alzheimer's Disease
Mayeux, R., Saunders, A. M., Shea, S., Mirra, S., Evans, D., Roses, A. D., Hyman, B. T., Crain, B., Tang, M.-X., & Phelps, C. H. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802193380804 · Cited by 547
Brain cytochrome oxidase in Alzheimer's disease
Kish, S. J., Bergeron, C., Rajput, A., Dozic, S., Mastrogiacomo, F., Chang, L., Wilson, J. M., DiStefano, L. M., & Nobrega, J. N. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb09439.x · Cited by 537
Dementia of the Alzheimer Type
Terry, R. D., & Davies, P. (1980) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.03.030180.000453 · Cited by 529
Amyloid β-protein deposition in tissues other than brain in Alzheimer's disease
Joachim, C. L., Mori, H., & Selkoe, D. J. (1989) · Nature · doi:10.1038/341226a0 · Cited by 462
Saunders, A., Hulette, C., Welsh-Bohmer, K., Schmechel, D., Crain, B., Burke, Jr., Alberts, M., Strittmatter, W., Breitner, J., Rosenberg, C., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)01251-2 · Cited by 253
Research works printed but not linked: 7
- Galasko, D.; Chang, L.; Motter, R., et al. High CSF tau and low A(42 in the clinical diagnosis of Alzheimer’s disease and relation to APOE genotype. Arch. Neurol. (in press).
- Arai, 1997, Elevated cerebrospinal fluid tau protein level as a predictor of dementia in memory-impaired individuals, Alzheimer’s Res., 3, 211
- Clark, C. M.; Ewbank, D.; Lee, V.; Trojanowski, J. Q. Molecular pathology of Alzheimer’s disease: Neuronal cytoskeletal abnormalities. In: Growdon, J. H.; Rossor, M., eds., The Dementias. Newton, MA: Butterworth Heinemann; (in press).
- Trojanowski, 1996, Elevated levels of tau in cerebrospinal fluid, Alzheimer’s Disease Review, 1, 77
- Gasparini, 1997, Inhibition of energy metabolism alters APP secretion in Alzheimer’s disease fibroblasts, Soc. Neurosci. Abs., 23, 332
- Hirashima, 1996, Calcium responses in human fibroblasts, Neurobiol. Aging, 17, 549, 10.1016/0197-4580(96)00074-7 · doi:10.1016/0197-4580(96)00074-7
- Zubenko, 1996, Prospective study of increased platelet membrane fluidity as a risk factor for Alzheimer’s disease, Am. J. Psychiatry, 153, 420, 10.1176/ajp.153.3.420 · doi:10.1176/ajp.153.3.420
Cited by
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Greicius, M. D., Srivastava, G., Reiss, A. L., & Menon, V. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308627101 · Cited by 3,684
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Metadata
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 1998-03
- Volume
- 19
- Issue
- 2
- Pages
- 109-116
- ISSN
- 0197-4580 (ISSN-L)
- OpenAlex
- W2511246053
- Cited by
- 666
- References
- 26
- FWCI
- 19.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 362 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”. https://app.cochat.ai/papers/10.1016/s0197-4580(98)00022-0
- The paper
- Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”. (1998). Neurobiology of Aging. https://doi.org/10.1016/s0197-4580(98)00022-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
